OmniAb, Inc. operates as a partner-driven technology provider enabling the discovery and optimization of next-generation biologic therapeutics. The company's core technology, referred to as Biological Intelligence, leverages proprietary transgenic animal models—including OmniRat, OmniMouse, OmniChicken, and OmniTaur—to produce highly optimized, fully human antibodies. In addition to its in vivo platforms, OmniAb offers advanced screening and artificial intelligence-driven optimization tools, such as the xPloration instrument and OmniDeep suite, to accelerate lead identification. The company supports hundreds of active partner programs across various therapeutic areas, including oncology, immunology, and infectious diseases. Rather than developing its own clinical pipeline, OmniAb captures value through upfront license fees, fee-for-service research, clinical milestone payments, and long-term royalties on approved drugs. Originally acquired by Ligand Pharmaceuticals, OmniAb was spun off as an independent public company in 2022.
